Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals
Frank J. Piscotta, Hans-Heinrich Hoffmann, Young Joo Choi, Gabriel I. Small, Alison W. Ashbrook, Bimal Koirala, Elizabeth A. Campbell, Seth A. Darst, Charles M. Rice, Sean F. Brady
Abstract
The continued prevalence of COVID-19 and the emergence of new variants has once again put the spotlight on the need for the identification of SARS-CoV-2 antivirals. The human microbiome produces an array of small molecules with bioactivities (e.g., host receptor ligands), but its ability to produce antiviral small molecules is relatively underexplored.
Topics & Concepts
MicrobiomeSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CommensalismCoronavirus disease 2019 (COVID-19)Human microbiomeBiology2019-20 coronavirus outbreakIdentification (biology)VirologyHost (biology)Computational biologyMicrobiologyMedicineBacteriaGeneticsEcologyInfectious disease (medical specialty)DiseasePathologyOutbreakGut microbiota and healthMetabolomics and Mass Spectrometry StudiesTryptophan and brain disorders